Sort by
Refine Your Search
-
Listed
-
Program
-
Employer
-
Field
-
Researcher (R2) Country Finland Application Deadline 15 Sep 2025 - 13:00 (UTC) Type of Contract Temporary Job Status Full-time Hours Per Week 38 Is the job funded through the EU Research Framework Programme
-
Doctoral Researcher in Solar & Space Physics The Space Physics Group at the University of Helsinki invites applications for a fully funded 4 year PhD position in solar and heliophysics. The position
-
’ qualifications and experience. Salary will increase as the PhD work progresses. How to apply? Please submit your application using the University of Helsinki recruitment system via the button “Apply now
-
Start date: Autumn 2025 Duration: 3 years, with a 1-year extension negotiable Location: Department of Computer Science, Aalto University, Helsinki, Finland Apply: Applications reviewed on a rolling
-
5 Sep 2025 Job Information Organisation/Company University of Turku Research Field Computer science Researcher Profile First Stage Researcher (R1) Country Finland Application Deadline 30 Sep 2025
-
Sini Laakso’s lab Autoimmune Neurology at the Translational Immunology Research Program at University of Helsinki, Faculty of Medicine invites applications for the position of POSTDOCTORAL
-
, writing articles, supervising M.Sc and possibly PhD students as well as contributing to teaching in the Master's Programme in Particle Physics and Astrophysical Sciences. The candidate should have: A good
-
degree (PhD or equivalent) in computer science, data science, statistics, bioinformatics, or a related discipline A strong publication record in machine learning, computer science, bioinformatics
-
plan and research proposal. For the doctoral researcher’s position, the appointee must enroll as a PhD student at the University of Helsinki. The appointee should either already have the right to pursue
-
experience in wet-lab and computational techniques. This position is intended for an MSc-level graduate planning to pursue a PhD degree. In this project, we aim to profile AML cancer cells treated with drug